Abstract CT205: A phase I dose-escalation study of trametinib (T) in combination with continuous or intermittent GSK2126458 (GSK458) in patients (pts) with advanced solid tumors
Bibliographic record
Abstract
Abstract Objectives: The primary objectives were to assess safety, tolerability and the maximum tolerated dose (MTD) for the combination of the PI3K/mTOR inhibitor GSK458 and the MEK inhibitor T. Methods: Pts with selected advanced solid tumors enriched for MAPK and PI3K pathway alterations, ECOG PS 0/1, with no history of diabetes, retinopathy or uncontrolled CNS disease were eligible. Three dosing schedules were evaluated: continuous (cont) once daily (QD) GSK458 and T; cont twice daily (BID) GSK458 and QD T; and intermittent (int) BID GSK458 (4 days on/10 days off) and cont QD T. Dose escalation followed a 3+3 design with dose limiting toxicity (DLT) evaluation during the first 28 days (NCT01248858). Results: From Dec/10-Oct/13, 69 pts were enrolled. The most frequent tumor types were colorectal (CRC) 29%, breast 16%, non-small cell lung (NSCLC) 10%, and pancreas 10%. A total of 12 dose levels were explored and 8 pts experienced DLTs that were reversible (Table). The MTD was exceeded at 0.5mg QD GSK458/2.0mg QD T and 0.5mg BID GSK458/1.5 mg QD T. Dose escalation was stopped before the MTD was defined for int GSK458 dosing because the tolerability of the combination was not improved. The most commonly reported drug-related AEs (≥20%) included rash 72%, diarrhea 54%, vomiting 33%, fatigue 30%, decreased appetite 23%, and stomatitis 22%, with dose interruptions for 51% of pts treated. No RECIST responses were observed. Stable disease >22 weeks occurred in 7 pts (KRASmt CRC, ocular melanoma, renal cell, KRASmt ovary (2), KRASmt small bowel, and KRASmt NSCLC). Conclusion: The MTDs of cont QD dosing are 1.0mg GSK458/1.5mg T and 2.0mg GSK458/1.0mg T. Tolerability of the combination was limited by rash, GI toxicity, fatigue and anorexia. A recommended phase 2 dose and schedule was not defined despite exploring alternative schedules including twice daily and intermittent dosing of GSK458. No further clinical development of the combination is planned. CohortGSK458TDLT(s)/EvaluableDLT event(s)10.5mg QD0.5mg QD0/320.5mg QD1.0mg QD0/431.0mg QD0.5mg QD0/440.5mg QD1.5mg QD0/551.0mg QD1.0mg QD1/6G2 folliculitis61.5mg QD1.0mg QD1/8G3 diarrhea70.5mg QD2.0mg QD3/5G3 stomatitis; G3 hypertension & G1 elevated troponin; G3 hypophosphatemia & G2 diarrhea82.0mg QD1.0mg QD0/691.0mg QD1.5mg QD0/7100.5mg BID1.5mg QD2/6Asymptomatic20% decrease LVEF; G3 mucositis110.5mg BID int1.5mg QD1/7G3 central serousretinopathy120.75mg BID int1.5mg QD0/5 Citation Format: Philippe L. Bedard, Juneko E. Grilley-Olson, Mark Cornfeld, Leanne Cartee, Susan Warwick, Albiruni A.R. Razak, Lee-Anne Stayner, Yuehui Wu, Rebecca Greenwood, Veronica Viana-Gilmartin, Carrie B. Lee, Johanna Bendell, Howard A. Burris, Luca Gianni, Cristiana Sessa, Jeffrey R. Infante, Angelica Fasolo. A phase I dose-escalation study of trametinib (T) in combination with continuous or intermittent GSK2126458 (GSK458) in patients (pts) with advanced solid tumors. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr CT205. doi:10.1158/1538-7445.AM2014-CT205
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.000 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".